Ulcerative ColitisNCT00793130
The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label
A study testing Coltect in people with Ulcerative Colitis, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
Trial summary
The aim of the study is to reduce the severity and duration of acute attacks, to prevent the recurrence of new acute attacks and to improve patient's quality of life. Coltect contains anti inflammatory and antioxidant natural agents (curcumin, green tea and selenomethionine) which are associated with a positive effect… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis
- What is being tested?
- Coltect
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteIsrael
- Study dates
- Nov 2008to Nov 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-75 years old.
- Subjects with mild to moderate active ulcerative colitis
- Hemoglobin value greater than 10 g/dL.
- Aspartate aminotransferase and alanine aminotransferase <1.5 times the upper limit of normal.
- Serum bilirubin and creatinine <1.5 × upper limit of normal.
- Subjects that provided informed consent and agree to comply with all study procedure.
Show all 10Show fewer
- Subjects had a Clinical Activity Index (CAI) >4
- Subjects had a Clinical Activity Index (CAI) ≤8
- Established or new diagnosis.
- Subjects that agreed to undergo sigmoidoscopy at study completion
Who cannot join
- Active chronic inflammatory or autoimmune disease other than UC.
- Active infection, including viral infection.
- Active peptic ulcer disease.
- Infectious/ Ischemic colitis.
- Acute or chronic cardiac, renal failure (serum creatinine >300 mmol/L)
- Abnormal liver function - (liver function tests greater than 1.5 times upper range of normal).
Show all 16Show fewer
- Crohn's disease.
- Use of rectal corticosteroids within 4 weeks before study entry.
- Patients with known or suspected bleeding tendency.
- Patients with severe active ulcerative colitis.
- Present or a history of colorectal cancer.
- Serious other disease(s) that according to physicians judgment should preclude the patient from participation in the study.
- Toxic megacolon.
- Prior bowel resection.
- Baseline positive stool culture or C DIFF toxin assay.
- Existing or intended pregnancy.
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Tel-Aviv Sourasky Medical Center
Tel Aviv, Gush-Dan, 64239
Iris Dotan, MD, +972-3-6947305, irisd@tasmc.health.gov.il
Nadir Arber, MD, +972-3-6974968, nadir@tasmc.health.gov.il
About this study
The aim of the study is to reduce the severity and duration of acute attacks, to prevent the recurrence of new acute attacks and to improve patient's quality of life.
Coltect contains anti inflammatory and antioxidant natural agents (curcumin, green tea and selenomethionine) which are associated with a positive effect on inflammatory disease.
The investigators assume that Coltect represents a tolerable and mild treatment, viable alternative to other medical therapies with fewer side effects.
Coltect is a food supplement that contains active ingredients from herbal sources.
Read the detailed description
Studies in animal models of colitis and in humans with IBD demonstrated that the components of Coltect have anti-inflammatory effects:
Hanai H. et al demonstrated that curcumin was safe and effective in maintaining remission in patients with quiescent UC. (7)
B.Salh et al showed that curcumin, was able to attenuate colitis in the dinitrobenzene sulfonic acid (DNB)-induced murine model of colitis. The immunohistochemical signal is dramatically attenuated at the level of the mucosa by curcumin. The authors thus proposed that curcumin may have therapeutic implications for human IBD. (8)
Potential Benefits of Coltect- Coltect might be suited for the treatment of patients with mild to moderate flare-ups of ulcerative colitis.
Coltect provides an effect with expected low incidence of side effects. (each agent tested before and found safe for human use).
The availability of a safe and effective non-surgical and non steroids treatment of active ulcerative colitis.
Overview - Clinical indication and summary of existing preclinical and clinical knowledge pertaining to the product.
Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
Curcumin is a natural compound found in the plant Curcuma longa which is used as a food additive known as turmeric. The major pigment in turmeric is curcumin - chemical name diferuloymethane, which possesses both anti-inflammatory and antioxidant properties. Curcumin also strongly inhibits proliferation of HT-29 and HCT-15 human colon cancer cell lines (1). Dietary administration of curcumin suppresses the development of chemically induced cancers(1). These properties have led to studies on the chemopreventive effects of curcumin which also showed that the agent reduces colonic inflammatory responses.
Curcumin has a profound immunosuppressive effect via inhibition of IL-2 synthesis as well as IL-2 and mitogen activation of human leukocytes. This immunosuppressive effect may be mediated by NFκB inhibition (1).
Based on the aforementioned, curcumin appears to reduce the inflammatory response in ulcerative colitis patients Clinical studies with curcumin have shown beneficial effects in experimental studies of acute and chronic diseases characterized by an exaggerated inflammatory reaction. There is an ample evidence to support its clinical use both in the prevention and a treatment setting. Several natural substances such as curcumin have greater antioxidant effects than conventional vitamins, including various polyphenols, flavonoids and curcumenoids. Natural substances are worth further research both experimentally and clinically.
Sting et al found that: Curcumin was shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation such as NFkB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS). (13)
Ricky A. Sharma et al designed a dose-escalation study to explore the pharmacology of curcumin in humans. Patients with advanced colorectal cancer consumed capsules compatible with curcumin doses between 0.45 and 3.6gr. daily for up to 4 months. Curcumin was well tolerated at all of the dose levels, and dose-limiting toxicity was not observed. At dose of 3.6gr. mild diarrhea is only discernible toxicity. (2) Cheng et al. treated patients with pre-malignant conditions with tablets containing pure curcumin for up to 3 months at daily dose as high as 8gr. without evident toxicity . They recommended that the common therapeutic dose would be 400-600 mg curcumin 3 times daily.(14)
Ricky el al showed that consumption of 3.6 g of curcumin daily causes inhibition of PGE2 production by blood leukocytes measured ex vivo.(2)
In therapy for UC, a double blind placebo-controlled trial with curcumin found that both the clinical and endoscopic evaluation scores were significantly improved by curcumin therapy. The endoscopic score was substantially improved compared with the placebo.
The results of this study indicate that the turmeric component, curcumin, is potentially a promising medication for the treatment of IBD (7)
Green tea is made from unfermented, solely leaves of Camellia sinensis and contains the highest concentration of powerful antioxidants called polyphenols.
The green tea polyphenols include (-)-epigallocatechin gallate (EGCG), (-) epigallocatechin (EGC), (-)-epicatechin gallate (ECG) and (-)-epicatechin (EC), they have potent antioxidant properties. (9) Gary et al provide evidence that green tea polyphenols have anti-inflammatory effects in murine colitis. They showed that mice treated with green tea polyphenols have less severe colitis, and green tea polyphenols are widely distributed throughout the body, one of the highest tissue concentrations is found in the intestine. This distribution favors its use in gastrointestinal diseases such as IBD.(9)
Selenium is an essential trace element with a worldwide average nutritional intake of 50 to 350 µg/d function as an antioxidant and anti inflammatory and associated with colorectal cancer prevention.(10,11) Marwan et al established the safety of administering high dose (2200 µg) of selenomethionine in humans with cancer up to 13 months. (12) Toxicity at high dose selenium appeared as mild headache, nausea or heartburn.
- Conditions
- Ulcerative Colitis
- Being tested
- Coltect
- Keywords
- Ulcerative, Colitis, Coltect, Curcumin, Green tea, Selenium, inflammation, bowel
- Medical subject headings
- Colitis, Ulcerative, Ulcer, Colitis, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ColtectDietary supplement
Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
| Study group | Role | What they receive |
|---|---|---|
| Coltect | Other | Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry. Receives: Dietary Supplement: Coltect |
What is being measured
The primary outcome is the main question the study is designed to answer.
50% improvement of the Clinical Activity Index (CAI) of the study.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2008 (estimated)
- Study startNov 2008
- Primary completionNov 2009 (estimated)
- Study completionNov 2009 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00793130
- Sponsor's protocol ID
- TASMC-08-ID-348-CTIL
- Status last verified
- Nov 2008
- First submitted
- 16 Nov 2008
- Last updated
- 19 Nov 2008
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label
- ClinicalTrials.gov ID
- NCT00793130
- Acronym / sponsor ID
- TASMC-08-ID-348-CTIL
- Conditions
- Ulcerative Colitis
- Keywords
- Ulcerative, Colitis, Coltect, Curcumin, Green tea, Selenium, inflammation, bowel
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Study start
- Nov 2008
- Primary completion
- Nov 2009 (estimated)
- Study completion
- Nov 2009 (estimated)
- First posted
- 19 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to reduce the severity and duration of acute attacks, to prevent the recurrence of new acute attacks and to improve patient's quality of life.
Coltect contains anti inflammatory and antioxidant natural agents (curcumin, green tea and selenomethionine) which are associated with a positive effect on inflammatory disease.
The investigators assume that Coltect represents a tolerable and mild treatment, viable alternative to other medical therapies with fewer side effects.
Coltect is a food supplement that contains active ingredients from herbal sources.
Detailed description
Studies in animal models of colitis and in humans with IBD demonstrated that the components of Coltect have anti-inflammatory effects:
Hanai H. et al demonstrated that curcumin was safe and effective in maintaining remission in patients with quiescent UC. (7)
B.Salh et al showed that curcumin, was able to attenuate colitis in the dinitrobenzene sulfonic acid (DNB)-induced murine model of colitis. The immunohistochemical signal is dramatically attenuated at the level of the mucosa by curcumin. The authors thus proposed that curcumin may have therapeutic implications for human IBD. (8)
Potential Benefits of Coltect- Coltect might be suited for the treatment of patients with mild to moderate flare-ups of ulcerative colitis.
Coltect provides an effect with expected low incidence of side effects. (each agent tested before and found safe for human use).
The availability of a safe and effective non-surgical and non steroids treatment of active ulcerative colitis.
Overview - Clinical indication and summary of existing preclinical and clinical knowledge pertaining to the product.
Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
Curcumin is a natural compound found in the plant Curcuma longa which is used as a food additive known as turmeric. The major pigment in turmeric is curcumin - chemical name diferuloymethane, which possesses both anti-inflammatory and antioxidant properties. Curcumin also strongly inhibits proliferation of HT-29 and HCT-15 human colon cancer cell lines (1). Dietary administration of curcumin suppresses the development of chemically induced cancers(1). These properties have led to studies on the chemopreventive effects of curcumin which also showed that the agent reduces colonic inflammatory responses.
Curcumin has a profound immunosuppressive effect via inhibition of IL-2 synthesis as well as IL-2 and mitogen activation of human leukocytes. This immunosuppressive effect may be mediated by NFκB inhibition (1).
Based on the aforementioned, curcumin appears to reduce the inflammatory response in ulcerative colitis patients Clinical studies with curcumin have shown beneficial effects in experimental studies of acute and chronic diseases characterized by an exaggerated inflammatory reaction. There is an ample evidence to support its clinical use both in the prevention and a treatment setting. Several natural substances such as curcumin have greater antioxidant effects than conventional vitamins, including various polyphenols, flavonoids and curcumenoids. Natural substances are worth further research both experimentally and clinically.
Sting et al found that: Curcumin was shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation such as NFkB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS). (13)
Ricky A. Sharma et al designed a dose-escalation study to explore the pharmacology of curcumin in humans. Patients with advanced colorectal cancer consumed capsules compatible with curcumin doses between 0.45 and 3.6gr. daily for up to 4 months. Curcumin was well tolerated at all of the dose levels, and dose-limiting toxicity was not observed. At dose of 3.6gr. mild diarrhea is only discernible toxicity. (2) Cheng et al. treated patients with pre-malignant conditions with tablets containing pure curcumin for up to 3 months at daily dose as high as 8gr. without evident toxicity . They recommended that the common therapeutic dose would be 400-600 mg curcumin 3 times daily.(14)
Ricky el al showed that consumption of 3.6 g of curcumin daily causes inhibition of PGE2 production by blood leukocytes measured ex vivo.(2)
In therapy for UC, a double blind placebo-controlled trial with curcumin found that both the clinical and endoscopic evaluation scores were significantly improved by curcumin therapy. The endoscopic score was substantially improved compared with the placebo.
The results of this study indicate that the turmeric component, curcumin, is potentially a promising medication for the treatment of IBD (7)
Green tea is made from unfermented, solely leaves of Camellia sinensis and contains the highest concentration of powerful antioxidants called polyphenols.
The green tea polyphenols include (-)-epigallocatechin gallate (EGCG), (-) epigallocatechin (EGC), (-)-epicatechin gallate (ECG) and (-)-epicatechin (EC), they have potent antioxidant properties. (9) Gary et al provide evidence that green tea polyphenols have anti-inflammatory effects in murine colitis. They showed that mice treated with green tea polyphenols have less severe colitis, and green tea polyphenols are widely distributed throughout the body, one of the highest tissue concentrations is found in the intestine. This distribution favors its use in gastrointestinal diseases such as IBD.(9)
Selenium is an essential trace element with a worldwide average nutritional intake of 50 to 350 µg/d function as an antioxidant and anti inflammatory and associated with colorectal cancer prevention.(10,11) Marwan et al established the safety of administering high dose (2200 µg) of selenomethionine in humans with cancer up to 13 months. (12) Toxicity at high dose selenium appeared as mild headache, nausea or heartburn.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Coltect | Other | Dietary Supplement: ColtectColtect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age 18-75 years old.
- Subjects with mild to moderate active ulcerative colitis
- Hemoglobin value greater than 10 g/dL.
- Aspartate aminotransferase and alanine aminotransferase <1.5 times the upper limit of normal.
- Serum bilirubin and creatinine <1.5 × upper limit of normal.
Key exclusion criteria (16 listed)
- Active chronic inflammatory or autoimmune disease other than UC.
- Active infection, including viral infection.
- Active peptic ulcer disease.
- Infectious/ Ischemic colitis.
- Acute or chronic cardiac, renal failure (serum creatinine >300 mmol/L)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ColtectTwo tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine. | Dietary supplement | Coltect |
Primary outcome
50% improvement of the Clinical Activity Index (CAI) of the study.
Time frame: 2 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2008.
Related trials for Ulcerative Colitis
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Coltect in people with Ulcerative Colitis, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Nov 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Iris Dotan, MD (+972-3-6947305, irisd@tasmc.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
50% improvement of the Clinical Activity Index (CAI) of the study. (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2008.